Latest Regulatory Approvals News

Element 25 Limited has made significant strides in advancing its Butcherbird Expansion Project in Western Australia, securing $60 million in funding and progressing key engineering and contract milestones. Simultaneously, the company moves closer to finalising financing for its US-based battery-grade manganese refinery.

Iron Road Ltd maintained modest spending on its Central Eyre Iron Project while progressing exploration at the Mulgathing Project, with key drilling results awaited. The company also updated its strategic land options at Cape Hardy amid subdued steel market conditions.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Emerald Resources NL has announced a significant update to its Dingo Range Gold Project in Western Australia, increasing its mineral resource to 1.41 million ounces of gold and securing full mining permits ahead of planned development in 2026.

Equus Energy has launched on the ASX with full ownership of the Equus Gas Project, backed by a $46 million conditional funding and gas sales agreement with Alcoa. The project aims to supply a significant new gas source for Western Australia’s LNG and domestic markets.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Rapid Critical Metals has launched a comprehensive scoping study for its NSW silver projects, backed by promising drilling results and advanced ore-sorting technology.

29Metals Limited has initiated a fully underwritten $150 million entitlement offer at $0.40 per share, aiming to bolster its growth projects and operational recovery following seismic disruptions. The retail offer opens on 28 January and closes on 11 February 2026.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.